These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37343270)

  • 1. Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes.
    Sako S; Takeshita Y; Takayama H; Goto H; Nakano Y; Ando H; Tsujiguchi H; Yamashita T; Arai K; Kaneko S; Nakamura H; Harada K; Honda M; Takamura T
    Diabetes; 2023 Sep; 72(9):1297-1306. PubMed ID: 37343270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Alexopoulos AS; Crowley MJ; Wang Y; Moylan CA; Guy CD; Henao R; Piercy DL; Seymour KA; Sudan R; Portenier DD; Diehl AM; Coviello AD; Abdelmalek MF
    Hepatology; 2021 Sep; 74(3):1220-1233. PubMed ID: 33724511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
    Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO
    Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
    Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
    World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
    Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
    Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
    Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
    J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis.
    He W; Huang C; Zhang X; Wang D; Chen Y; Zhao Y; Li X
    Endocrine; 2021 Jul; 73(1):52-64. PubMed ID: 33837926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.